Your browser doesn't support javascript.
loading
Efficacy of trabectedin in metastatic solitary fibrous tumor.
Chaigneau, Loïc; Kalbacher, Elsa; Thiery-Vuillemin, Antoine; Fagnoni-Legat, Christine; Isambert, Nicolas; Aherfi, Lionel; Pauchot, Julien; Delroeux, Delphine; Servagi-Vernat, Stephanie; Mansi, Laura; Pivot, Xavier.
Afiliação
  • Chaigneau L; Department of Medical Oncology, Universitary Hospital Center J. Minjoz, Besançon, France;
Rare Tumors ; 3(3): e29, 2011 Jul 11.
Article em En | MEDLINE | ID: mdl-22066036
Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19%, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is the complete resection of primary tumor. Treatment of recurrences is not clearly established. If a solitary fibrous tumor is too advanced to allow surgical resection, radiotherapy and chemotherapy may be used. The most often used drugs are doxorubicine and\or ifosfamide. We report the case of man with metastatic solitary fibrous tumor treated with trabectedin, administered at a dose of 1.5 mg/m² every 3 weeks. After 3 cycles, metastases had significantly decreased. Recurrence of the disease was demonstrated 8 months after the start of trabectedin. This case shows that trabectedin is a possible treatment option.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2011 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2011 Tipo de documento: Article